Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM8BOFB)

Drug Name	ADP-A2M10 DM8BOFB
Drug Type	CAR-T cell therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

4 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-small-cell lung cancer	DISI0V1B	2C25	Phase 1	[1]
Melanoma	DIS1RRCY	2C30	Phase 1	[2]
Bladder cancer	DISUHNM0	2C94	Phase 1	[2]
Head and neck cancer	DISBPSQZ	2D42	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.
2	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022 Mar 18;12:818679.